Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT324 + BNT327 in advanced lung cancer (Phase Ib/II, China)
ChiCTR2500106775Phase 2Not yet recruiting
- Sponsor
- Jilin Provincial Cancer Hospital
- Start
- Jul 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of db-1311 and pumitamig in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (10 arms), sponsored by Jilin Provincial Cancer Hospital. Primary endpoints: Objective response rate, Dose-limiting toxicity and 6 more. Planned start Jul 2025; status: not yet recruiting.
02
Drugs
db-1311pumitamig
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2500106775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500106775.